Literature DB >> 31122487

A new step towards targeting tau.

Jean-Christophe Corvol1, Luc Buée2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31122487     DOI： 10.1016/S1474-4422(19)30161-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

1.  The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ε4 Non-carriers.

Authors:  Pascual Sánchez-Juan; Sonia Moreno; Itziar de Rojas; Isabel Hernández; Sergi Valero; Montse Alegret; Laura Montrreal; Pablo García González; Carmen Lage; Sara López-García; Eloy Rodrííguez-Rodríguez; Adelina Orellana; Lluís Tárraga; Mercè Boada; Agustín Ruiz
Journal:  Front Aging Neurosci       Date:  2019-12-04       Impact factor: 5.750

2.  BrightFocus Alzheimer's Fast Track 2019.

Authors:  Keith W Whitaker; Frank M LaFerla; Harry W M Steinbusch; Cynthia A Lemere; Diane E Bovenkamp
Journal:  Mol Neurodegener       Date:  2019-12-20       Impact factor: 14.195

3.  MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties.

Authors:  Nipun Chopra; Ruizhi Wang; Bryan Maloney; Kwangsik Nho; John S Beck; Naemeh Pourshafie; Alexander Niculescu; Andrew J Saykin; Carlo Rinaldi; Scott E Counts; Debomoy K Lahiri
Journal:  Mol Psychiatry       Date:  2020-01-15       Impact factor: 15.992
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.